What question did this study set out to answer?

The aim is to highlight the risk of interstitial pneumonitis following carmustine administration even at lower doses.

A41-09 Fatal Carmustine-induced Interstitial Pneumonitis Following Autologous Hematopoietic Stem Cell Transplant at a Subthreshold Dose

View Full Paper

Ask AI

Bookmark

Authors

Case report reveals fatal interstitial pneumonitis in a patient following carmustine treatment, suggesting careful monitoring is essential.

The aim is to highlight the risk of interstitial pneumonitis following carmustine administration even at lower doses.
Described a case of a 59-year-old female with PCNSL who developed acute respiratory failure after carmustine and thiotepa conditioning.
Conducted bronchoalveolar lavage and chest CT to evaluate pulmonary changes post-transplantation.
Monitored pulmonary function tests and blood gas analyses prior to and during treatment.
Patient experienced progressive dyspnea and hypoxia after receiving 400 mg/m² of carmustine.
Chest CT showed ground-glass opacities, and bronchoalveolar lavage revealed inflammatory cells without infectious etiology.
Despite high-dose corticosteroid treatment, the patient succumbed to progressive interstitial pneumonitis.

Kamel et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Case report reveals fatal interstitial pneumonitis in a patient following carmustine treatment, suggesting careful monitoring is essential.